<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238563</url>
  </required_header>
  <id_info>
    <org_study_id>7/8/05-21</org_study_id>
    <nct_id>NCT00238563</nct_id>
  </id_info>
  <brief_title>Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery</brief_title>
  <official_title>Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Determine efficacy of sub tenon kenalog injections for post-operative management of
      trabeculectomy procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative sub-Tenon Triamcinolone Acetonide in glaucoma filtering surgery

      Objectives: Trabeculectomy is a surgical procedure designed to reduce internal eye pressure
      by draining fluid from within the eye to the sub-conjunctival (superficial eye lining)
      space. Scar formation from conjunctival and Tenon's capsule fibroblast proliferation
      represents the most common cause of failure of trabeculectomies. A number of drugs have been
      use to prevent failure of trabeculectomies from the scarring process including
      intraoperative mitomycin C (MMC) and preoperative Triamcinalone Acetonide (TA). Over the
      past several years, intraoperative MMC has become a preferred method of preventing scar
      formation. This study looks to determine in a prospective, double-blind, randomized method
      the long-term efficacy and safety of MMC with postoperative TA compared to the standard
      practice of intraoperative MMC with postoperative prednisolone acetate drops in preventing
      scar related failures of trabeculectomies.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual field progression, need for further surgery or medications</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Glaucoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone injection, sub-tenon</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Trabeculectomy surgery patient, age 18 or older - Exclusion
        Criteria:Pregnant, nursing, age less than 18, known allergy to medication being studied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Santa Clara valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher J Engelman, MD</last_name>
      <phone>408-885-6770</phone>
      <email>engelman@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher J Engelman, MD</last_name>
      <phone>408-885-6770</phone>
      <email>engelman@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher James Engelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <lastchanged_date>February 22, 2008</lastchanged_date>
  <firstreceived_date>October 11, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
